![](/images/2013/post-sep.jpg)
Ainnocence Unveils SentinusAI®: Revolutionizing Antibody Design, Conquering Undruggable Targets, Rescuing Failed Trials
Transforming Cancer Immunotherapies with AI-Driven Discovery and Optimization
SAN FRANCISCO, CALIFORNIA, UNITED STATES, August 5, 2024 /EINPresswire.com/ -- Ainnocence today announced the launch of SentinusAI®, a groundbreaking AI platform for precision antibody design. This proprietary technology redefines antibody discovery by tackling undruggable targets, rescuing failed clinical trials, and extending patent life.
The SentinusAI® platform is an AI-powered protein design engine that enhances antibody affinity and addresses challenging targets, including membrane and secreted proteins. It combines advanced epitope mapping with de novo hit generation, affinity maturation, off-target screening, humanization, and developability optimization.
This comprehensive approach can virtually screen up to 10^10 antibody sequences within hours to days, accelerating the development of life-saving therapies for previously intractable targets. The platform is also able to deliver a shortlist of candidates with a high wet lab hit rate, accelerating the development of life-saving therapies.
SentinusAI's platform designs various antibody formats, including full-length IgG antibodies, antibody fragments (Fab, scFv, VHH), bispecific and multispecific formats, and constructs for antibody-drug conjugates and CAR-T applications.
It excels in designing bispecific antibodies targeting CD3, BCMA, and other cancer-related targets, as well as high-affinity antibodies for antibody-drug conjugates (e.g., Her2, CD22, CD30), addressing solid tumor penetration challenges and maximizing therapeutic index.
Key Advantages of the SentinusAI Platform:
1. Unmatched sequence space exploration
AI algorithms efficiently analyze billions of sequences, identifying high-affinity, humanized antibody candidates.
2. Rapid turnaround
Powered by AWS elastic cloud computing and Nvidia GPU, computational delivery occurs within one week, with antibody production and testing within a month.
3. Wide applicability
Suitable for numerous therapeutic targets, including:
Membrane proteins: CD19, CD20, PD-L1, CTLA-4, HER2, EGFR, CD22, CD33, CD30, CD56, CD123, CD133, CD45, CD47, CD95, VEGFR, FGFR, MET, ALK, HER2, HER3
Secreted targets: IL-2, IL-6, TNF-α, IFN-γ, IL-17A, IL-10, IL-1β, TGF-β, M-CSF, GM-CSF, VEGF, FGF, HGF, EGF, IGF, PDGF, RANTES, MCP-1, MIP-1α, SDF-1
These targets are crucial for cancer immunotherapy, autoimmune diseases, and chronic inflammatory conditions.
4. Cost-effective
Significantly reduces R&D time and costs compared to conventional phage display, hybridoma, or B-cell sequencing methodologies.
5. Ethical and sustainable
Eliminates the need for animal screening in antibody generation and testing.
Beyond therapeutics, SentinusAI® applies to industrial enzymes, agriculture, diagnostics, and environmental solutions, revolutionizing protein-based innovation across industries.
This launch marks a significant milestone for Ainnocence and the pharmaceutical industry, promising to develop highly effective therapeutics and improve global health outcomes through artificial intelligence.
About Ainnocence:
Ainnocence is revolutionizing drug discovery with our next-generation, self-evolving AI platform. We offer unparalleled speed and precision in virtual screening and pharmacological profile optimization for various therapeutic modalities.
To explore how our AI-driven innovation can transform your drug discovery process, visit www.ainnocence.com or follow us on LinkedIn.
Lurong Pan, PhD
CEO and Founder, Ainnocence
email us here
![](https://lungcancer.einnews.com/tracking/article.gif?aid=731879986§ion=einpresswire&a=fewKzYkXyS5IfUO2&i=HfJyZrDrT5XY03cF)
Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry, Science, Technology
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release